Jeffrey Hung
Stock Analyst at Morgan Stanley
(4.37)
# 329
Out of 5,182 analysts
236
Total ratings
49.65%
Success rate
19.52%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeffrey Hung
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $50 → $67 | $24.10 | +178.01% | 10 | Apr 16, 2026 | |
| NBIX Neurocrine Biosciences | Maintains: Equal-Weight | $173 → $185 | $130.22 | +42.07% | 33 | Apr 10, 2026 | |
| BCYC Bicycle Therapeutics | Maintains: Equal-Weight | $13 → $12 | $4.93 | +143.41% | 7 | Apr 8, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Overweight | $150 → $136 | $84.92 | +60.15% | 15 | Mar 17, 2026 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $225 → $226 | $199.03 | +13.55% | 13 | Feb 25, 2026 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $90 → $92 | $70.63 | +30.26% | 14 | Feb 23, 2026 | |
| CTNM Contineum Therapeutics | Downgrades: Equal-Weight | $23 → $14 | $13.15 | +6.46% | 5 | Jan 8, 2026 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Overweight | $77 → $80 | $38.90 | +105.66% | 4 | Jan 6, 2026 | |
| CYTK Cytokinetics | Maintains: Overweight | $65 → $71 | $65.80 | +7.90% | 14 | Dec 23, 2025 | |
| BIOA BioAge Labs | Upgrades: Equal-Weight | $5 → $12 | $19.61 | -38.81% | 3 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $19 | $8.51 | +123.27% | 5 | Nov 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $56 → $79 | $71.84 | +9.97% | 5 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $28 | $14.22 | +96.91% | 7 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $4 → $2 | $22.41 | -91.08% | 4 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $102 → $108 | $14.46 | +646.89% | 5 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $24 | $21.80 | +10.09% | 25 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $85 | $69.08 | +23.05% | 6 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $27 | $39.49 | -31.63% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $3.89 | +799.74% | 1 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $10 → $4 | $4.62 | -13.42% | 10 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $1 → $4 | $1.59 | +151.57% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $14 | $5.55 | +152.25% | 3 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $5 | $4.11 | +21.65% | 1 | Jul 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $9 → $3 | $1.92 | +56.25% | 8 | Mar 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $50 → $10 | $1.22 | +719.67% | 3 | Jan 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $23 → $22 | $45.89 | -52.06% | 10 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $146 → $149 | $10.19 | +1,357.31% | 2 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $100 → $60 | $0.91 | +6,513.03% | 5 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $6 | $4.12 | +45.63% | 9 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $696 → $648 | $10.77 | +5,916.71% | 6 | May 8, 2020 |
Ultragenyx Pharmaceutical
Apr 16, 2026
Maintains: Overweight
Price Target: $50 → $67
Current: $24.10
Upside: +178.01%
Neurocrine Biosciences
Apr 10, 2026
Maintains: Equal-Weight
Price Target: $173 → $185
Current: $130.22
Upside: +42.07%
Bicycle Therapeutics
Apr 8, 2026
Maintains: Equal-Weight
Price Target: $13 → $12
Current: $4.93
Upside: +143.41%
Rhythm Pharmaceuticals
Mar 17, 2026
Maintains: Overweight
Price Target: $150 → $136
Current: $84.92
Upside: +60.15%
Jazz Pharmaceuticals
Feb 25, 2026
Maintains: Overweight
Price Target: $225 → $226
Current: $199.03
Upside: +13.55%
PTC Therapeutics
Feb 23, 2026
Maintains: Overweight
Price Target: $90 → $92
Current: $70.63
Upside: +30.26%
Contineum Therapeutics
Jan 8, 2026
Downgrades: Equal-Weight
Price Target: $23 → $14
Current: $13.15
Upside: +6.46%
Crinetics Pharmaceuticals
Jan 6, 2026
Maintains: Overweight
Price Target: $77 → $80
Current: $38.90
Upside: +105.66%
Cytokinetics
Dec 23, 2025
Maintains: Overweight
Price Target: $65 → $71
Current: $65.80
Upside: +7.90%
BioAge Labs
Dec 8, 2025
Upgrades: Equal-Weight
Price Target: $5 → $12
Current: $19.61
Upside: -38.81%
Nov 12, 2025
Maintains: Overweight
Price Target: $18 → $19
Current: $8.51
Upside: +123.27%
Sep 17, 2025
Maintains: Overweight
Price Target: $56 → $79
Current: $71.84
Upside: +9.97%
Aug 18, 2025
Maintains: Overweight
Price Target: $35 → $28
Current: $14.22
Upside: +96.91%
Aug 18, 2025
Downgrades: Equal-Weight
Price Target: $4 → $2
Current: $22.41
Upside: -91.08%
Jul 17, 2025
Upgrades: Overweight
Price Target: $102 → $108
Current: $14.46
Upside: +646.89%
May 20, 2025
Maintains: Equal-Weight
Price Target: $20 → $24
Current: $21.80
Upside: +10.09%
Mar 7, 2025
Assumes: Overweight
Price Target: $85
Current: $69.08
Upside: +23.05%
Mar 7, 2025
Assumes: Overweight
Price Target: $27
Current: $39.49
Upside: -31.63%
Jul 26, 2024
Initiates: Overweight
Price Target: $35
Current: $3.89
Upside: +799.74%
Dec 19, 2023
Downgrades: Underweight
Price Target: $10 → $4
Current: $4.62
Upside: -13.42%
Dec 19, 2023
Upgrades: Equal-Weight
Price Target: $1 → $4
Current: $1.59
Upside: +151.57%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $14
Current: $5.55
Upside: +152.25%
Jul 11, 2023
Reiterates: Equal-Weight
Price Target: $5
Current: $4.11
Upside: +21.65%
Mar 20, 2023
Maintains: Equal-Weight
Price Target: $9 → $3
Current: $1.92
Upside: +56.25%
Jan 30, 2023
Downgrades: Underweight
Price Target: $50 → $10
Current: $1.22
Upside: +719.67%
Nov 2, 2022
Maintains: Equal-Weight
Price Target: $23 → $22
Current: $45.89
Upside: -52.06%
May 11, 2022
Maintains: Equal-Weight
Price Target: $146 → $149
Current: $10.19
Upside: +1,357.31%
Aug 13, 2021
Downgrades: Underweight
Price Target: $100 → $60
Current: $0.91
Upside: +6,513.03%
Apr 19, 2021
Maintains: Equal-Weight
Price Target: $7 → $6
Current: $4.12
Upside: +45.63%
May 8, 2020
Maintains: Overweight
Price Target: $696 → $648
Current: $10.77
Upside: +5,916.71%